Semaglutide Treatment Shows Promising Results in Reducing Alcohol Use Disorder Symptoms

A collaboration between the University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences has published the first evidence showing that semaglutide, a drug used for diabetes and weight loss, is associated with significant reductions in symptoms of Alcohol Use Disorder (AUD). The study outlines the outcomes of six patients who received semaglutide during weight loss treatment and experienced a noteworthy decrease in their Alcohol Use Disorders Identification Test (AUDIT) scores. This research opens up new possibilities for the use of semaglutide in addiction medicine, but further investigation through larger, controlled studies is needed to validate and expand upon these initial findings.